DK0526503T3 - Polymerer som kontrastmedier til magnetisk resonansimagografi - Google Patents

Polymerer som kontrastmedier til magnetisk resonansimagografi

Info

Publication number
DK0526503T3
DK0526503T3 DK91908011.9T DK91908011T DK0526503T3 DK 0526503 T3 DK0526503 T3 DK 0526503T3 DK 91908011 T DK91908011 T DK 91908011T DK 0526503 T3 DK0526503 T3 DK 0526503T3
Authority
DK
Denmark
Prior art keywords
magnetic resonance
resonance imaging
polymers
contrast media
polymer
Prior art date
Application number
DK91908011.9T
Other languages
English (en)
Inventor
Evan C Unger
Original Assignee
Imarx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imarx Pharmaceutical Corp filed Critical Imarx Pharmaceutical Corp
Application granted granted Critical
Publication of DK0526503T3 publication Critical patent/DK0526503T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Signal Processing (AREA)
  • Dispersion Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Graft Or Block Polymers (AREA)
DK91908011.9T 1990-04-10 1991-04-09 Polymerer som kontrastmedier til magnetisk resonansimagografi DK0526503T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50712590A 1990-04-10 1990-04-10

Publications (1)

Publication Number Publication Date
DK0526503T3 true DK0526503T3 (da) 1997-10-27

Family

ID=24017359

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91908011.9T DK0526503T3 (da) 1990-04-10 1991-04-09 Polymerer som kontrastmedier til magnetisk resonansimagografi

Country Status (8)

Country Link
EP (2) EP0526503B1 (da)
JP (1) JPH05506227A (da)
AT (2) ATE153860T1 (da)
DE (2) DE69126429T2 (da)
DK (1) DK0526503T3 (da)
ES (2) ES2103809T3 (da)
GR (1) GR3023806T3 (da)
WO (1) WO1991015753A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
US5948387A (en) * 1990-06-01 1999-09-07 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
CA2081560A1 (en) * 1990-06-01 1991-12-02 Evan C. Unger Contrast media for ultrasonic imaging
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
WO1993010440A1 (en) * 1991-11-19 1993-05-27 Unger Evan C Gel particle contrast media for improved diagnostic imaging
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
CA2146990A1 (en) * 1992-10-14 1994-04-28 Robert A. Snow Chelating polymers
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
EP0664713B1 (en) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
AU687093B2 (en) 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
DE19942278C2 (de) * 1999-09-04 2001-09-13 Messer Griesheim Gmbh Quantitative Bestimmung des Xenongehaltes in Flüssigkeiten mit Hilfe der NMR-Spektroskopie
CN101321806B (zh) 2005-12-05 2011-01-26 日东电工株式会社 聚谷氨酸盐-氨基酸轭合物及方法
US20090162291A1 (en) * 2006-05-17 2009-06-25 Otsuka Pharmaceutical Co., Ltd. Magnetic resonance contrast medium using polyethylene glycol and magnetic resonance image pick-up method
CA2683590A1 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
KR101303567B1 (ko) * 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법
CN107206111B (zh) 2014-12-31 2021-04-27 蓝瑟斯医学影像公司 脂质封装的气体微球组合物及相关方法
AU2017260532B2 (en) 2016-05-04 2024-08-22 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
EP0184899B1 (en) * 1984-11-01 1990-04-18 Nycomed As Paramagnetic contrast agents for use in "in vivo" diagnostic methods using nmr, and their preparation
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
JPS62153229A (ja) * 1985-12-27 1987-07-08 Nippon Oil Co Ltd 皮膚マ−カ−
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4729892A (en) * 1986-03-21 1988-03-08 Ciba-Geigy Corporation Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials
US4933441A (en) * 1987-01-27 1990-06-12 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
GB8813425D0 (en) * 1988-06-07 1988-07-13 Hall L D Magnetic resonance imaging
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions

Also Published As

Publication number Publication date
ES2138122T3 (es) 2000-01-01
GR3023806T3 (en) 1997-09-30
DE69126429D1 (de) 1997-07-10
ATE153860T1 (de) 1997-06-15
ES2103809T3 (es) 1997-10-01
DE69131721T2 (de) 2000-03-02
WO1991015753A1 (en) 1991-10-17
DE69131721D1 (de) 1999-11-18
EP0526503A4 (en) 1993-02-24
DE69126429T2 (de) 1997-10-23
ATE185489T1 (de) 1999-10-15
EP0526503B1 (en) 1997-06-04
EP0526503A1 (en) 1993-02-10
EP0693288A1 (en) 1996-01-24
EP0693288B1 (en) 1999-10-13
JPH05506227A (ja) 1993-09-16

Similar Documents

Publication Publication Date Title
DK0526503T3 (da) Polymerer som kontrastmedier til magnetisk resonansimagografi
DE69231830D1 (de) Gasgefüllte Mikrospheren enthaltende Kontrastmittel zur diagnostischen Bilderzeugung
FI960546A (fi) Polymeerin stabilointi stabiililla vapaalla radikaalilla
EP0728486A3 (en) Contrast media for ultrasonic imaging
CY1110818T1 (el) Φορεας εγγραφων και διαταξη σαρωσης του φορεα εγγραφων
DE68924207D1 (de) System zur Ermittlung des optimalen Brennpunkts eines optischen Plattensystems.
DE69101914D1 (de) Verzweigte fructo-oligosacchariden, verfahren zu ihrer herstellung und verwendung von diese enthaltenden mitteln.
DE3769517D1 (de) Magnetisches aufzeichnungsmedium und verfahren zu dessen herstellung.
DE69130344D1 (de) Optisches Aufzeichnungsmedium, Verfahren zur optischen Aufzeichnung und Verfahren zur optischen Wiedergabe
DE68904582D1 (de) Elektroakoustische membran und verfahren zur herstellung.
DE69104815D1 (de) Gaslaser-Oszillationsvorrichtung und Methode zur Justierung seiner optischen Achse.
DE69110945D1 (de) Magnetisches Aufzeichnungsmedium.
DE69205920D1 (de) Modulation eines Injektionslasers.
DE60206056D1 (de) Herstellung von polymerteilchen
DE69013700D1 (de) Optische Trägerplatte, optisches Informationsspeichermedium und Verfahren zur Herstellung der optischen Trägerplatte.
NO920936D0 (no) Poroes, termoplastisk membranstruktur
DE3788069D1 (de) Optomagnetisches speichermedium und verfahren zur herstellung.
ATE180676T1 (de) Adjuvans für impstoffe
DE59000772D1 (de) Seitenstaendige carbazolyl-gruppen enthaltende methacrylat-(co)polymerisate und elektrophotographische aufzeichnungselemente, enthaltend dieselben.
DE3766872D1 (de) Magnetisches aufzeichnungsmedium und verfahren zu dessen herstellung.
DE58907891D1 (de) Verfahren zur Sterilisation von intraocularen Linsen.
DE3886832D1 (de) Magnetischer Aufzeichnungsträger und Methode zu seiner Herstellung.
DE69013819D1 (de) Magnetisches Aufzeichnungsmedium.
DE69714702D1 (de) Verfahren zur Herstellung von 2-Hydroxy-Ethyl-Methacrylat-Polymere, Hydrogel und Wasser enthaltender weicher Kontaklinse
ES2162062T3 (es) Estabilizacion de nitrilos.